TABLE 1.
Patient characteristics at baseline and previous treatment strategies.
| Patient characteristics (Candidates for upadacitinib treatment) (n = 19) | |
| Male,n (%) | 8 (42.1) |
| Female,n(%) | 11 (57.9) |
| Age, median (min-max) | 33 (19–46) |
| BMI, median (min-max) | 22.5 (16.9–40.8) |
| Duration of AD, median (min-max) | 33 (19–46) |
| Family history of atopic disease,n (%) | 7 (36,8) |
| Previous treatmentstrategy, n (%) | |
| Topical steroids | 19 (100) |
| Emollients | 19 (100) |
| Dupilumab | 1 (5.3) |
| Systemic steroids | 11 (57.9) |
| Cyclosporin | 2 (10.5) |
| PUVA-therapy | 4 (21) |
| Atopic comorbidities, n (%) | |
| Combination of bronchial asthma and allergic rhinoconjunctivitis Of these, severe bronchial asthma |
7 (36.8) 0 |
| Hay fever | 8 (42.1) |
| Food allergy | 6 (31.6) |
| None | 3 (15.8) |
| Allergen sensitization | |
| Dust mites | 12 |
| Epidemal | 13 |
| Pollen | 14 |
| Molds | 10 |
| Food | 17 |
| Monosensitisation Of these, epidermal Of these, dust mites |
3 2 1 |
| Polysensitisation | 15 |
| Not revealed | 1 |
| Comorbidities, n (%) | |
| Obesity | 1 |
| Iron deficiency anemia | 3 |
| Beta-thalassemia | 1 |
| Sinusitis | 2 |
| Arterial hypertension | 2 |
| Tonsillitis | 1 |
| Chronic urticaria | 1 |
| Laboratory data | |
| tIgE, IU/mL, median (min-max), [normal range] | 1,959 (30–8123), [0–100] |
| Absolute number of eosinophils, cells per microliter, median (min-max), [normal range] | 325 (0–2290), [30–300] |
BMI, body mass index; tIgE, total IgE.